- ￥440 - 3700
- Solarbio
- 北京
- IA5170
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件：
Powder:-20℃，1 year;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:-20℃，1 year;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
Angiotensin
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
51833-78-4
- 规格：
50mg/25mg/10mg/2mg/5mg
| 规格： | 50mg | 产品价格： | ￥3700.0 |
|---|---|---|---|
| 规格： | 25mg | 产品价格： | ￥2320.0 |
| 规格： | 10mg | 产品价格： | ￥1040.0 |
| 规格： | 2mg | 产品价格： | ￥440.0 |
| 规格： | 5mg | 产品价格： | ￥660.0 |
是肾素-血管紧张素系统 (RAS) 中的一种内源性七肽,由于其在心肌细胞中的抗炎和抗纤维化活性而具有心脏保护作用。Angiotensin 1-7 通过抑制血管紧张素转换酶和释放一氧化氮,可作为激肽诱导的血管舒张的局部协同调节剂。据报道,Angiotensin 1-7 抑制纯化的犬血管紧张素转换酶(ACE)活性。Angiotensin 1-7 阻断 Ang II 诱导的平滑肌细胞增殖和肥大,并显示对内皮的抗血管生成和生长抑制作用。
| 基本信息 | |
| CAS | No.51833-78-4 |
| 中文名称 | 1-7 血管紧张素 (1-7) |
| 英文名称 | Angiotensin |
| 别名 | Ang-(1-7);ASP-ARG-VAL-TYR-ILE-HIS-PRO |
| 分子式 | C41H62N12O11 |
| 分子量 | 899 |
| 溶解性 | Soluble in Water |
| 纯度 | ≥98% |
| 外观(性状) | White to off-white Solid |
| 储存条件 | Powder:-20℃，1 year;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| SMILES | O=C(N(CCC1)[C@@H]1C(O)=O)[C@@H](NC([C@@]([C@@H](C)CC)([H])NC([C@@H](NC([C@H](C(C)C)NC([C@H](CCCNC(N)=N)NC([C@@H](N)CC(O)=O)=O)=O)=O)CC2=CC=C(O)C=C2)=O)=O)CC3=CNC=N3 |
| InChIKey | PVHLMTREZMEJCG-GDTLVBQBSA-N |
| InChI | InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1 |
| PubChem CID | 123805 |
| 靶点 | Angiotensin Receptor |
| 通路 | GPCR & G Protein |
| 背景说明 | 是肾素-血管紧张素系统 (RAS) 中的一种内源性七肽,由于其在心肌细胞中的抗炎和抗纤维化活性而具有心脏保护作用。Angiotensin 1-7 通过抑制血管紧张素转换酶和释放一氧化氮,可作为激肽诱导的血管舒张的局部协同调节剂。据报道,Angiotensin 1-7 抑制纯化的犬血管紧张素转换酶(ACE)活性。Angiotensin 1-7 阻断 Ang II 诱导的平滑肌细胞增殖和肥大,并显示对内皮的抗血管生成和生长抑制作用。 |
| 生物活性 | Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .[1-5] |
| In Vitro | Angiotensin 1-7 (Ang-(1-7)) inhibits cultured vascular smooth muscle cell growth， whereas equal molar concentration of Ang II stimulates cell growth[2].? Angiotensin 1-7 (Ang 1-7) abrogates the methylglyoxal-modified albumin (MGA)-stimulated myofibroblast phenotype by inhibiting the chronic stimulation of the TGF-β-ERK pathway in NRK-52E cells[4]. Angiotensin 1-7 signals through the Mas receptor ( MasR) in opposition to Ang II/angiotensin II type 1 receptor (AT1R)， promoting anti-inflammatory，vasodilatory， and neuroprotective effects[5]. |
| 细胞实验 | Daily Angiotensin 1-7 (Ang-(1-7)) treatment (0.01-0.06 mg/kg) results in significant amelioration of DSS-induced colitis. Colitis-associated phosphorylation of p38， ERK1/2 and Akt is reduced by Ang 1-7 treatment[3]. |
| 细胞实验 | 500 μM Methylglyoxal is incubated with 100 μM BSA dissolved in phosphate buffered saline (PBS) for 24 hours， then washed on 10 kDa filters to remove excess methyl glyoxal， reconstituted with DMEM/F12 serum free media and passed through a 0.2 μmicron filter. TGF-β (5 ng/mL) is prepared to treat cells in a subset of experiments. Cells are co-treated with one or combinations of the following: Angiotensin (1-7) (100 nM)， D-Ala7-Ang-(1-7) (10 μM)， ERK1/2 kinase inhibitor， PD 98059 (1 μM)， TGF-β receptor kinase inhibitor; SB525334 (1 μM)， the AT1 receptor antagonist Losartan (1 μM)， the renin inhibitor Aliskerin (1 μM) and the ACE inhibitor Lisinopril (1 μM)[2]. |
| 动物实验 | Mice[3] Male and female BALB/c mice (1:1 ratio， 6-10 weeks old， mean weight 20 g.) are used. Angiotensin fragment 1-7 acetate salt hydrate (Ang 1-7) is dissolved in 0.9% saline (vehicle) at 1 mg/mL and stored at -80°C. Various doses (0.01， 0.06， 0.1， 0.3 and 1 mg/kg) are freshly prepared from the stock each day of the experiment， and administered to mice by daily intra-peritoneal (i.p) injections in a volume of 500 μL per injection， either before (prophylactic approach) or after (treatment approach) DSS treatment. A779 (MAS-1 R antagonist) is similarly dissolved in distilled water at 1 mg/mL and stored at -80°C. A freshly prepared dose of 1 mg/kg is administered to a second group of mice by daily i.p injections in a volume of 500 μL daily (for 4 days) along with colitis induction (prophylactic approach). A third group of mice receive DSS containing water and daily i.p injections of 0.9% saline (vehicle). The fourth group receive DSS containing water along with daily i.p injections with Dexamethasone (DEX) at doses of 0.01-1.0 mg/kg or its vehicle (0.9% saline) (prophylactic approach). Rats[4] Twenty six ovariectomized female Wistar rats weighing 200±20 g are used. Angiotensin (1-7) is administered intravenously by a microsyringe pump at two different continuous doses of 100 and 300 ng/kg/min after antagonist/saline infusion. Each dose is infused for 15 min; and MAP， RPP， and RBF are recorded during Angiotensin (1-7) infusion and the last 3-5 min of each dose measured as “response to Angiotensin (1-7) infusion”. During Angiotensin (1-7) infusion， RPP is sustained at pre-Ang1-7 infusion levels via an adjustable aortic clamp. |
| 激酶实验 | Competition assays using purified canine ACE are determined using a fixed concentration of the substrate Hip-His-Leu (1 mM) and varying the concentrations of the competing agents [Lisinopril (0.1 to 100 nM)， Angiotensin (1-7) (10 nM to 10 μM)， or Sar1， Thr8-Ang II (10 nM to 10 μM)]. Inhibitory constants (IC50) are determined from the respective competition curves. To study the effect of Angiotensin (1-7) on BK metabolism in intact coronary rings， 125I-[Tyr0]-BK (final concentration of 1 nM) is added to the tubes containing three rings preincubated with 1 mL Krebs buffer and aerated with 95% O2 and 5% CO2 at 37°C. Lisinopril (2 μM)， Angiotensin (1-7) (2 μM)， or Krebs buffer as control are added to the rings 10 minutes before addition of the radiolabeled BK. Aliquots of the incubation medium are removed at 5， 10， and 20 minutes and diluted with 1% HFBA to inhibit peptidase activity[1]. |
| 数据来源文献 | [1]. Gómez-Mendoza DP， et al. Angiotensin-(1-7) oral treatment after experimental myocardial infarction leads to downregulation of CXCR4. J Proteomics. 2019;208:103486. [2]. Li P， et al. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997 Jan;29(1 Pt 2):394-400. [3]. Khajah MA， et al. Anti-Inflammatory Action of Angiotensin 1-7 in Experimental Colitis. PLoS One. 2016 Mar 10;11(3):e0150861. [4]. Alzayadneh EM， et al. Angiotensin-(1-7) abolishes AGE-induced cellular hypertrophy and myofibroblast transformation via inhibition of ERK1/2. Cell Signal. 2014 Sep 19. pii: S0898-6568(14)00314-3. [5]. Janatpour ZC， et al. Subcutaneous Administration of Angiotensin-(1-7) Improves Recovery after Traumatic Brain Injury in Mice. J Neurotrauma. 2019;36(22):3115-3131. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
IA5170 1-7 血管紧张素 (1-7) Peptides 索莱宝
￥440 - 3700
